Mice lacking cathepsin K maintain bone remodeling but develop bone fragility despite high bone mass

Journal of Bone and Mineral Research

Volumn 21, Issue 6, 2006, Pages 865-875

  Li, Chao Yang ^a   Jepsen, Karl J ^a   Majeska, Robert J ^a   Zhang, Jian ^a   Ni, Rujing ^a   Gelb, Bruce D ^a   Schaffler, Mitchell B ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Bone biomechanics; Bone histomorphometry; Cathepsin K; Intracortical remodeling; Osteopetrosis

Indexed keywords

CATHEPSIN K;

ALBERS SCHOENBERG DISEASE; ANIMAL TISSUE; ARTICLE; BIOMECHANICS; BONE DEVELOPMENT; BONE FRAGILITY; BONE MASS; BONE REMODELING; BONE STRUCTURE; BONE TURNOVER; CELL FUNCTION; CONTROLLED STUDY; CORTICAL BONE; CTSK GENE; DISEASE MODEL; DYSOSTOSIS; ENZYME ACTIVITY; ENZYME DEFICIENCY; FEMALE; FEMUR; GENE; MALE; METAPHYSIS; MORPHOMETRICS; MOUSE; MOUSE STRAIN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PHENOTYPE; PYKNODYSOSTOSIS; THICKNESS;

ANIMALS; BONE DENSITY; BONE REMODELING; CATHEPSINS; DISEASE MODELS, ANIMAL; FEMALE; FRACTURES, BONE; GENETIC PREDISPOSITION TO DISEASE; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOPETROSIS;

EID: 33646870167     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.060313     Document Type: Article

References (32)

1. Hasserius R, Karlsson MK, Jonsson B, Redlund-Johnell I, Johnell O 2005 Long-term morbidity and mortality after a clinically diagnosed vertebral fracture in the elderly-a 12- and 22-year follow-up of 257 patients. Calcif Tissue Int 76:235-242.
2. Grey A, Reid IR 2005 Emerging and potential therapies for osteoporosis. Expert Opin Investig Drugs 14:265-278.
3. Genant HK, Cooper C, Poor G, Reid I, Ehrlich G, Kanis J, Nordin BEC, Barrett-Connor E, Black D, Bonjour JP, Dawson-Hughes B, Delmas PD, Dequeker J, Eis SR, Gennari C, Johnell O, Johnston CC Jr, Lau EMC, Liberman UA, Lindsay R, Martin TJ, Masri B, Mautalen CA, Meunier PJ, Miller PD, Mithal A, Morii H, Papopoulos S, Woolf A, Yu W, Khaltaev N 1999 Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 10:259-264.
4. Rosen, CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, De Papp AE, Actonel Comparison Trial Investigators 2005 Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: A randomized double-blind study. J Bone Miner Res 20:141-151.
5. Saftig P, Hunziker E, Wehmeyer O, Jones S, Boyde A, Rommerskirch W, Moritz JD, Schu P, von Figura K 1998 Impaired osteoclastic bone resorption leads to osteopetrosis in cathepsin K-deficient mice. Proc Natl Acad Sci USA 95:13453-13458.
6. Gowen M, Lazner F, Dodds R, Kapadia R, Field J, Tavari M, Bertoncello I, Drake F, Zavarselk S, Tellis I, Hertzog P, Debouck C, Kola I 1999 Cathepsin K knockout mice develop osteopetrosis due to a deficit in matrix degradation but not demineralization. J Bone Miner Res 14:1654-1663.
7. Kiviranta R, Morko J, Alatalo SL, Nicamhlaoibh R, Risteli J, Laitala-Leinonen T, Vuorio E 2005 Impaired bone resorption in cathepsin K-deficient mice is partially compensated for by enhanced osteoclastogenesis and increased expression of other proteases via an increased RANKL/OPG ratio. Bone 36:159-172.
8. Gelb BD, Shi GP, Chapman HA, Desnick RJ 1996 Pyknodysostosis, a lysosomal disease caused by cathepsin K deficiency. Science 273:1236-1238.
9. Fratzl-Zelman N, Valenta A, Roschger P, Nader A, Gelb BD, Fratzl P, Klaushofer K 2004 Decreased bone turnover and deterioration of bone structure in two cases of pyknodysostosis. J Clin Endocrinol Metab 89:1538-1547.
10. Novartis http://novartis.com/investors/en/ir_archive/_and_d2003 Accessed April 7, 2006.
11. Sorian P, Montgomery C, Geske R, Bradley A 1991 Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64:693-702.
12. Tondravi MM, McKercher SR, Anderson K, Erdmann JM, Quiroz M, Maki R, Teitelbaum SL 1997 Osteopetrosis in mice lacking haematopoietic transcription factor PU.1. Nature 386:81-84.
13. Wang ZQ, Ovitt C, Grigoriadis AE, Mohle-Steinlein U, Ruther U, Wagner EF 1992 Bone and haematopoietic defects in mice lacking c-fos. Nature 360:741-745.
14. Jepsen KJ, Akkus O, Majeska RJ, Nadeau JH 2003 Hierarchical relationship between bone traits and mechanical properties in inbred mice. Mamm Genome 14:97-104.
15. Li CY, Majeska RJ, Laudier DM, Mann R, Schaffler MB 2005 High dose risedronate treatment partially preserves cancellous bone mass and microarchitecture during long-term disuse. Bone 37:287-295.
16. Parfitt AM, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry nomenclature, symbols and units: Report of the ASBMR Histomorphometry Nomenclature Committee. J Bone Miner Res 2:595-610.
17. Stroup GB, Lark MW, Veber DF, Bhattacharyya A, Blake S, Dare LC, Erhard KF, Hoffman SJ, James IE, Marquis RW 2001 Potent and selective inhibition of human cathepsin K leads to inhibition of bone resorption in vivo in a nonhuman primate. J Bone Miner Res 16:1739-1746.
18. Kneissel M, Luong-Nguyen NH, Baptist M, Cortesi R, Zumstein-Mecker S, Kossida S, O'Reilly T, Lane H, Susa M 2004 Everolimus suppresses cancellous bone loss, bone resorption, and cathepsin K expression by osteoclasts. Bone 35:1144-1156.
19. Nikawa T, Ikemoto M, Watanabe C, Kitano T, Kano M, Yoshimoto M, Towatari T, Katunuma N, Shizuka F, Kishi K 2002 A cysteine protease inhibitor prevents suspension-induced declines in bone weight and strength in rats. J Physiol Anthropol Appl Human Sci 21:51-57.
20. Li CY, Price C, Delisser K, Nasser P, Laudier D, Clement M, Jepsen KJ, Schaffler MB 2005 Long-term disuse osteoporosis seems less sensitive to bisphosphonate treatment than other osteoporosis. J Bone Miner Res 20:117-124.
21. Lotinun S, Evans GL, Bronk JT, Bolander ME, Wronski TJ, Ritman EL, Turner RT 2004 Continuous parathyroid hormone induces cortical porosity in the rat: Effects on bone turnover and mechanical properties. J Bone Miner Res 19:1165-1171.
22. Aro HT, Wippermann BW, Hodgson SF, Chao EY 1990 Internal remodeling of periosteal new bone during fracture healing. J Orthop Res 8:238-246.
23. Mandelin J, Hukkanen M, Li TF, Korhonen M, Liljeström M, Sillat T, Hanemaaijer R, Salo J, Santavirta S, Konttinen YT. 2005 Human osteoblasts produce cathepsin K. Bone (in press).
24. Pennypacker BL, Shea M, Saftig P, Rodan SB, Rodan GA, Kimmel DB 1999 Bone density and strength in cathepsin K null mice. J Bone Miner Res 14:S1;SU472.
25. Jepsen KJ, Schaffler MB, Kuhn JL, Goulet RW, Bonadio J, Goldstein SA 1997 Type I collagen mutation alters the strength and fatigue behavior of Mov13 cortical tissue. J Biomech 30:1141-1147.
26. Everts V, Korper W, Janse DC, Steinfort J, Lammerse I, Heera S, Dochert AJ, Beertsen W 1999 Functional heterogeneity of osteoclasts: Matrix metalloproteinases participate in osteoclastic resorption of calvarial bone but not in resorption of long bone. FASEB J 13:1219-1230.
27. Everts V, Delaissé JM, Korper W, Jansen DC, Tigchelaar-Gutter W, Saftig P, Beertsen W 2002 The bone lining cell: Its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 17:77-90.
28. Hou WS, Brömme D, Zhao Y, Mehler E, Dushey C, Weinstein H, Miranda CS, Fraga C, Greig F, Carey J, Rimoin DL, Desnick RJ, Gelb BD 1999 Characterization of novel cathepsin K mutations in the pro and mature polypeptide regions causing pyknodysostosis. J Clin Invest 103:731-738.
29. Matsumura S, Oue N, Nakayama H, Kitadai Y, Yoshida K, Yamaguchi Y, Imai K, Nakachi K, Matsusaki K, Chayama K, Yasui W 2005 A single nucleotide polymorphism in the MMP-9 promoter affects tumor progression and invasive phenotype of gastric cancer. J Cancer Res Clin Oncol 131:19-25.
30. Wallace AM, Sandford AJ 2002 Genetic polymorphisms of matrix metalloproteinases: Functional importance in the development of chronic obstructive pulmonary disease? Am J Pharmacogenomics 2:167-175.
31. Zhang B, Henney A, Eriksson P, Hamsten A, Watkins H, Ye S 1999 Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet 105:418-423.
32. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr D 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620.